Strides Shasun Limited (BSE: 532531, NSE: STAR) today announced its Q4 FY18 and FY 18 results
Performance Highlights – Q4 FY18 and FY 18 INR Mn
| Particulars | Q1 FY18 | Q2 FY18 | Q3 FY 18 | Q4 FY 18 | FY18 | FY17 | YoY |
| Revenues | 6,547 | 7,721 | 7,534 | 6,775 | 28,576 | 27,581 | 4% |
| EBITDA | 834 | 1,129 | 1,401 | 1,005 | 4,369 | 6,027 | (28%) |
| EBITDA % | 13% | 15% | 19% | 15% | 15% | 22% | (650 Bps) |
| Adj PAT | 52** | 1,304* | |||||
| Adj EPS | 0.6** | 14.6* |
*For FY18 – Adj for Stelis share of loss INR 144Mn, restructuring expense & others of INR 210Mn, CHC loss 446Mn
*For Q4FY18 – Adj for Stelis share of loss INR 43Mn, restructuring expense & others INR 36Mn, CHC loss 106 Mn
Arun Kumar, Group CEO and Managing Director, remarked, “The financial year 2017-18 was a difficult year for Strides. While we continue to build momentum with our strategy, our execution was far from satisfactory. We completed several of our corporate actions including exiting non-core operations and markets that did not add value to our overall goal of being a diversified B2C player globally”
“We are particularly happy with the strategic progression at Arrow in Australia to become a leading and a profitable player. We are geared for a combination with Apotex to create an industry-leading position in Australia both by value and volume. We expect the transaction to achieve closure in the next two-quarters subject to regulatory approvals.”
“In 2018-19 our clear focus will be on the improving the quality of growth which will deliver a strong bounce back in the second half of FY 19”
Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 2 facilities for the emerging markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries.
